Bevacizumab: A Controversial Agent Against High-Grade Gliomas
نویسندگان
چکیده
منابع مشابه
An Overview of Fotemustine in High-Grade Gliomas: From Single Agent to Association with Bevacizumab
Fotemustine is a third-generation nitrosourea showing efficacy in various types of tumors such as melanoma and glioma. We reviewed the most important studies on fotemustine treatment in glioma patients analyzing its pharmacological profile and its activity and safety. Fotemustine was used as single agent or in association with new targeted drugs such as bevacizumab; fotemustine was used both as...
متن کاملBevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges
High-grade gliomas continue to have dismal prognosis despite advances made in understanding the molecular genetics, signaling pathways, cytoskeletal dynamics, and the role of stem cells in gliomagenesis. Conventional treatment approaches, including surgery, radiotherapy, and cytotoxic chemotherapy, have been used with limited success. Therapeutic advances using molecular targeted therapy, immun...
متن کاملBevacizumab is active as a single agent against recurrent malignant gliomas.
Bevacizumab, a humanized monoclonal antibody designed to inhibit vascular endothelial growth factor, is effective in combination with chemotherapy against malignant gliomas. We examined the therapeutic effects and toxicity of bevacizumab as a single agent for the treatment of recurrent malignant glioma. This is a retrospective analysis of a case series of 18 adult patients, diagnosed with recur...
متن کاملBevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
PURPOSE Although patients with newly diagnosed WHO grade 3 malignant glioma have a more favorable prognosis than those with WHO grade 4 malignant glioma, salvage therapies following recurrence offer essentially palliative benefit. We did a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irinotecan for patients with recurrent grade ...
متن کاملMR perfusions imaging of anti angiogenic (bevacizumab) treatment in patients with recurrent high grade gliomas
Introduction: Perfusion MRI has become a powerful tool for evaluating brain tumors (1). Anti-angiogenic therapy using bevacizumab (Avastin) affects abnormal neovascularity which is a hallmark of high grade primary brain tumors. Alterations in neovascularity result in hemodynamic changes; therefore, perfusion imaging would be an ideal surrogate for assessing the effects of anti-angiogenic therap...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JHN Journal
سال: 2011
ISSN: 2325-2839
DOI: 10.29046/jhnj.006.2.002